Satellos is pioneering an original approach in regenerative medicine. We are developing small molecule drugs to stimulate innate tissue repair. Applicable to many tissue types, our initial application is muscle repair. Satellos is based on the discovery in our founder's labs of a key regulatory mechanism influencing the stem cell fate decision governs mitotic stem cell division which enables asymmetry. This process, called polarity, enables a stem cell to create one daughter cell which is a tissue precursor and one stem cell which sustains the pool. We have demonstrated the ability to influence this process with drug to stimulate intrinsic muscle repair in a mouse model of Duchenne muscular dystrophy. Our approach has potential in numerous muscle wasting and neuro-degenerative diseases. We are seeking Series A funding of $25M to complete our drug discovery efforts, undertake preclinical studies and fund Phase I/II clinical studies.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):